Ayano C. Kohlgruber

Ayano C. Kohlgruber

Auto-generated profile, based on publicly available information

Ayano C. Kohlgruber

Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Boston, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2021 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
NLNoella Lopes
Noella Lopes
CMClaire McIntyre
Claire McIntyre
SMStefania Martin
Stefania Martin
MRMathilde Raverdeau
Mathilde Raverdeau
NSNital Sumaria
Nital Sumaria
LLLydia Lynch
Lydia Lynch

2 July 2024 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
AKAyano C. Kohlgruber
Ayano C. Kohlgruber
Mohammad Haj DezfulianMohammad Haj Dezfulian
Mohammad Haj Dezfulian
BSBrandon M. Sie
Brandon M. Sie
CWCharlotte I. Wang
Charlotte I. Wang
TKTomasz Kula
Tomasz Kula
SEStephen J. Elledge
Stephen J. Elledge
Antigen discovery technologies have largely focused on major histocompatibility complex (MHC) class I-restricted human T cell receptors (TCRs), leaving methods for MHC class II-restricted and mouse TCR reactivities relatively undeveloped. Here we present TCR mapping of antigenic peptides (TCR-MAP), an antigen discovery method that uses a synthetic TCR-stimulated circuit in immortalized T cells to activate sortase-mediated tagging of engineered antigen-presenting cells (APCs) expressing processed peptides on MHCs. Live, tagged APCs can be directly purified for deconvolution by sequencing, enabling TCRs with unknown specificity to be queried against barcoded peptide libraries in a pooled screening context. TCR-MAP accurately captures self-reactivities or viral reactivities with high throughput and sensitivity for both MHC class I-restricted and class II-restricted TCRs. We elucidate problematic cross-reactivities of clinical TCRs targeting the cancer/testis melanoma-associated antigen A3 and discover targets of myocarditis-inciting autoreactive T cells in mice. TCR-MAP has the potential to accelerate T cell antigen discovery efforts in the context of cancer, infectious disease and autoimmunity.

1 October 2018 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
NLNelson M. LaMarche
Nelson M. LaMarche
AKAyano C. Kohlgruber
Ayano C. Kohlgruber
MBMichael B. Brenner
Michael B. Brenner
During the past 25 y, the immune system has appeared as a key regulator of adipose tissue biology and metabolic homeostasis. In lean animals, adipose-resident leukocytes maintain an anti-inflammatory microenvironment that preserves the proper functioning of the tissue. In this review, we describe two populations of innate T cells enriched in adipose tissue, invariant NKT and γδ T cells, and how they serve overlapping and nonredundant roles in controlling adipose tissue functions. These cells interact with and expand anti-inflammatory regulatory T cells and M2 macrophages, thereby driving a metabolically beneficial tissue milieu. Surprisingly, we have found that adipose invariant NKT and γδ T cells also promote weight loss and heat production in a process called “nonshivering thermogenesis.” The data surrounding these two cell types highlight their powerful ability to regulate not only other leukocytes, but also tissue-wide processes that affect an entire organism.

24 August 2016 in Radiation Research
Verified
Journal Article
Open access
PDF file
DEDavid A. Edmondson
David A. Edmondson
EKErin E. Karski
Erin E. Karski
AKAyano Kohlgruber
Ayano Kohlgruber
HKHarsha Koneru
Harsha Koneru
KMKatherine K. Matthay
Katherine K. Matthay
MCMatthew Coleman
Matthew Coleman
Calculating internal dose from therapeutic radionuclides currently relies on estimates made from multiple radiation exposure measurements, converted to absorbed dose in specific organs using the Medical Internal Radiation Dose (MIRD) schema. As an alternative biodosimetric approach, we utilized gene expression analysis of whole blood from patients receiving targeted radiotherapy. Collected blood from patients with relapsed or refractory neuroblastoma who received 131I-labeled metaiodobenzylguanidine (131I-mIBG) at the University of California San Francisco (UCSF) was used to compare calculated internal dose with the modulation of chosen gene expression. A total of 40 patients, median age 9 years, had blood drawn at baseline, 72 and 96 h after 131I-mIBG infusion. Whole-body absorbed dose was calculated for each patient based on the cumulated activity determined from injected mIBG activity and patient-specific time-activity curves combined with 131I whole-body S factors. We then assessed transcripts that were the most significant for describing the mixed therapeutic treatments over time using real-time polymerase chain reaction (RT-PCR). Modulation was evaluated statistically using multiple regression analysis for data at 0, 72 and 96 h. A total of 10 genes were analyzed across 40 patients: CDKN1A; FDXR; GADD45A; BCLXL; STAT5B; BAX; BCL2; DDB2; XPC; and MDM2. Six genes were significantly modulated upon exposure to 131I-mIBG at 72 h, as well as at 96 h. Four genes varied significantly with absorbed dose when controlling for time. A gene expression biodosimetry model was developed to predict absorbed dose based on modulation of gene transcripts within whole blood. Three transcripts explained over 98% of the variance in the modulation of gene expression over the 96 h (CDKN1A, BAX and DDB2). To our knowledge, this is a novel study, which uses whole blood collected from patients treated with a radiopharmaceutical, to characterize biomarkers that may be useful for biodosimetry. Our data indicate that transcripts, which have been previously identified as biomarkers of external exposures in ex vivo whole blood and in vivo radiotherapy patients, are also good early indicators of internal exposure. However, for internal sources of radiation, the biokinetics and physical decay of the radionuclide strongly influence the gene expression.